



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Rybrevent (amivantamab-vmjw)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Rybrevent 350mg/7mL solution for injection Dose: _____ Frequency of therapy: _____ Duration of therapy: _____ ICD10: _____					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Other (please specify): _____ <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Home Health / Home Infusion vendor <i>**Cigna's nationally preferred specialty pharmacy</i> 					
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
<p style="text-align: center;">NOTE: Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting</p> Is this infusion occurring in a facility affiliated with hospital outpatient setting? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If yes- Is this patient a candidate for re-direction to an alternate setting (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale):					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Diagnosis related to use: <input type="checkbox"/> non-small cell lung cancer (NSCLC) <input type="checkbox"/> other (please specify: _____)					
Clinical Information					
(if NSCLC) Does your patient have locally advanced or metastatic disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
(if NSCLC) Does your patient have epidermal growth factor receptor (EGFR) exon 20 insertion mutations? <input type="checkbox"/> Yes <input type="checkbox"/> No					
(if NSCLC, if exon 20) Will this medication be used as first line treatment in combination with carboplatin and pemetrexed? <input type="checkbox"/> Yes <input type="checkbox"/> No					
(if no) Will the medication be used as a single agent treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No					
(if yes) Has the patient's disease progressed on or after platinum-based chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					

(if NSCLC, if not exon 20) Does your patient have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations? Yes No

(if exon 19/21) Is/Will this medication (be)ing used in combination with lazertinib? Yes No

(if exon 19/21) Is this the first treatment your patient has received for this diagnosis? Yes No

(if no) Is/Will this medication (be)ing used as continuation of therapy with disease progression on amivantamab-vmjw with lazertinib? Yes No

(if continuation) Which of the following best describes the patient's disease?

- asymptomatic disease
- symptomatic brain lesions
- symptomatic systemic limited progression
- none of the above

Additional pertinent information *Additional Pertinent information (please include disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v020125

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005